Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 1/20 | 0.41 |
| ▸ | TNK2 | Q07912 | 4/20 | 0.39 |
| ▸ | SRC | P12931 | 3/20 | 0.37 |
| ▸ | RAF1 | P04049 | 2/20 | 0.37 |
| ▸ | AURKA | O14965 | 1/20 | 0.37 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.37 |
| ▸ | KDR | P35968 | 7/20 | 0.37 |
| ▸ | ABL1 | P00519 | 2/20 | 0.37 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.37 |
| ▸ | EGFR | P00533 | 1/20 | 0.37 |
| ▸ | INSR | P06213 | 1/20 | 0.37 |
| ▸ | IGF1R | P08069 | 1/20 | 0.37 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.37 |
| ▸ | ATP4A | P20648 | 2/20 | 0.35 |
| ▸ | ATP4B | P51164 | 2/20 | 0.35 |
| ▸ | RET | P07949 | 6/20 | 0.35 |
| ▸ | PRKDC | P78527 | 1/20 | 0.35 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
| ▸ | ATR | Q13535 | 1/20 | 0.35 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4790960 | 0.76 | RAF1 (0.44) | TNK2SRCRAF1KDRABL1 | |
| SCHEMBL594916 | 0.72 | TNK2 (0.67) | TNK2SRCRAF1KDRABL1 | |
| SCHEMBL594915 | 0.72 | TNK2 (0.67) | TNK2SRCRAF1KDRABL1 | |
| SCHEMBL4391984 | 0.72 | IGF1R (0.39) | TNK2AURKBKDREGFRINSR | |
| SCHEMBL5080364 | 0.71 | IGF1R (0.36) | TNK2AURKBKDREGFRINSR | |
| SCHEMBL5085414 | 0.68 | TNK2 (0.38) | TNK2 | |
| SCHEMBL5083455 | 0.68 | DHFR (0.34) | INSRIGF1R | |
| SCHEMBL595275 | 0.62 | RAF1 (0.67) | TNK2SRCRAF1KDRABL1 | |
| SCHEMBL595274 | 0.62 | RAF1 (0.67) | TNK2SRCRAF1KDRABL1 | |
| SCHEMBL23641151 | 0.62 | GSK3B (0.62) | GSK3BAURKAAURKBKDRATP4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090274698-A1 | Combination anti-cancer therapy | OSI PHARMACEUTICALS, INC. | 2009-11-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090274698-A1 | Combination anti-cancer therapy | MTOR, RICTOR, AKT1 | GSK3B 471/4885TNK2 144/4885SRC 151/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.